Local Consolidative Radiotherapy Combined With Immunochemotherapy for De Novo Metastatic Nasopharyngeal Carcinoma: A Meta‐Analysis
Head & Neck · 2026-12 · 48 (12) · 3399-3410
DOI: 10.1002/hed.70366 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Head & Neck, online erschienen am 28.06.2026. Verfasst von Li Ma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China. Hauptthemen laut MEDLINE: Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Immunotherapy, Chemoradiotherapy. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Shenzhen Science and Technology Innovation Program, Shenzhen Key Medical Discipline Construction Fund, Sanming Project of Medicine in Shenzhen.
Abstract (Originalsprache)
Background
Immunochemotherapy is the standard care of newly diagnosed metastatic nasopharyngeal carcinoma (NPC). Limited trials with small sample sizes reported the potential benefit of delivering radiotherapy in these patients. The purpose of our systematic review and meta‐analysis was to examine the efficacy and toxicity of local consolidative radiotherapy when combined with immunochemotherapy as the first‐line treatment in newly diagnosed metastatic NPC, providing a reference for clinicians to make the best choice in clinical practice.
Methods
A comprehensive search was conducted in PubMed, Embase, Cochrane Library, Medline, and CNKI to identify published literature between January 1, 2004 and June 30, 2025 to identify potential eligible studies, including patients with pathologically confirmed de novo metastatic NPC treated with radiotherapy and immunochemotherapy. Toxicity rates, progression‐free survival (PFS), and overall survival (OS) for the endpoints of interest were extracted from the articles, and the 95% confidence intervals (CIs) were estimated. The systematic review and meta‐analysis were conducted in accordance with the PRISMA 2020 Statement, and the study protocol was prospectively registered in PROSPERO (CRD42024607034).
Results
Seven studies with a total of 802 patients were analyzed to evaluate the efficacy and toxicity of first‐line local radiotherapy and immunochemotherapy in newly diagnosed metastatic NPC. The results showed that the addition of consolidative radiotherapy to immunochemotherapy significantly improved PFS in de novo metastatic NPC (HR = 0.48 [0.38, 0.60]) using a fixed‐effects model ( I 2 = 44%, p = 0.15). The random‐effects pooled result indicated that consolidative radiotherapy added to immunochemotherapy failed to improve OS (HR = 0.52, 95% CI: 0.18–1.61, I 2 = 59%, p = 0.12). The pooled event rates of toxicities are 62.52% (95% CI: 25.22%–92.73%, I 2 = 97.8%), 63.03% (95% CI: 29.6%–90.6%, I 2 = 97.2%), 57.54% (95% CI: 30.72%–82.15%, I 2 = 95.6%), 21.29% (95% CI: 8.08%–39.37%, I 2 = 91.2%), 7.12% (95% CI: 0.33%–21.55%, I 2 = 87.1%) for mucositis, dermatitis, xerostomia, ear toxicity, and trismus of all grades, respectively. Grade 3–4 mucositis, dermatitis, xerostomia, ear toxicity, and trismus were 9.57% (95% CI: 3.37%–18.49%, I 2 = 79.4%), 3.5% (95% CI: 1.87%–5.63%, I 2 = 19.3%), 0.39% (95% CI: 0.01%–1.29%, I 2 = 37.4%), 1.37% (95% CI: 0.01%–4.95%, I 2 = 69.3%), and 0.26% (95% CI: 0%–1.25%, I 2 = 0%), respectively.
Conclusions
Local consolidative radiotherapy combined with immunochemotherapy in de novo metastatic NPC may improve PFS, whereas no statistically significant OS benefit was observed. Of note, the OS finding should be interpreted cautiously given the limited studies available for pooled OS analysis. The pooled toxicity rate derived in this systematic review and meta‐analysis can be a guide for clinical decision‐making and patient management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Förderung
- Shenzhen Science and Technology Innovation Program
- Shenzhen Key Medical Discipline Construction Fund
- Sanming Project of Medicine in Shenzhen
- Shenzhen High-Level Hospital Construction Fund, Shenzhen Clinical Research Center for Cancer
- CAMS Innovation Fund for Medical Sciences (CIFMS)
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union M…
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- Sanming Project of Medicine in Shenzen Municipality
Zitieren
APA
Ma, L., Fu, F., Wang, W., Zhou, Y., Zhang, J., & Qiu, S. (2026). Local Consolidative Radiotherapy Combined With Immunochemotherapy for De Novo Metastatic Nasopharyngeal Carcinoma: A Meta‐Analysis. Head & Neck, 48(12), 3399-3410. https://doi.org/10.1002/hed.70366
Vancouver
Ma L, Fu F, Wang W, Zhou Y, Zhang J, Qiu S. Local Consolidative Radiotherapy Combined With Immunochemotherapy for De Novo Metastatic Nasopharyngeal Carcinoma: A Meta‐Analysis. Head & Neck. 2026;48(12):3399-3410. doi:10.1002/hed.70366
BibTeX
@article{Ma2026,
author = {Ma, Li and Fu, Fangmeng and Wang, Wenxi and Zhou, Yangmei and Zhang, Jianghu and Qiu, Sufang},
title = {Local Consolidative Radiotherapy Combined With Immunochemotherapy for De Novo Metastatic Nasopharyngeal Carcinoma: A Meta‐Analysis},
journal = {Head & Neck},
year = {2026},
volume = {48},
number = {12},
pages = {3399--3410},
doi = {10.1002/hed.70366}
}
EUVIMED